Closed · W81XWH-20-PRCRP-IPA · CFDA 12.420 · Discretionary
DoD Peer Reviewed Cancer Research, Impact Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- August 27, 2020
- Close date
- 11
- Expected awards
The verdict
DoD Peer Reviewed Cancer Research, Impact Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 11 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.
- Varies
- award range
- Closed
- application status
- 11
- expected awards
- 12.420
- CFDA program
Archived opportunity record
DoD Peer Reviewed Cancer Research is closed (last close August 27, 2020). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed August 27, 2020
Est. Total Funding
$17,600,000
Expected Awards
11
Instrument
Grant
Description
Award mechanism encourages applications with mature research projects that specifically focus on critical scientific or clinical cancer issues, which, if successfully addressed, have the potential to make a major impact on at least one of the FY20 PRCRP Topic Areas. Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples and trials. Through the Impact Award, the PRCRP seeks to build foundations in under-funded, under-studied, and/or lethal militarily relevant cancer or research areas. The Impact Award supports identifying scientific outcomes through rigorous, robust research that are translatable toward treatment and/or preventive strategies. Research proposed should aim to accelerate promising findings toward clinical applicability and leverage research results to maximize impact. The critical components of this award mechanism are: · Impact: The Impact Award is intended to support research that demonstrates the potential to have a major impact in the near term on an area of paramount importance in cancer. The proposed study should demonstrate how the research will transform cancer research toward improved patient outcomes in at least one of the FY20 PRCRP Topic Areas. The research should make a significant shift toward clinical applicability in at least one of the FY20 PRCRP Topic Areas. Proposed projects may include translational or clinical research, including clinical trials. The potential impact of the proposed research is expected to be near-term and it must be significant and go beyond an incremental advance. The applicant must articulate the potential impact the proposed work will have on cancer research and/or patient outcomes. The Impact Award is not intended for basic research. Applicants posing more basic or long term impact studies should apply to the FY20 PRCRP Idea Award (W81XWH-20-PRCRP-IA). · Preliminary Data: The Impact Award is intended to support transformative investigations that leapfrog the cancer research field forward by utilizing previous research findings. Applications must include preliminary data to support feasibility of the study. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team. · Continuity of Research: The Impact Award is intended to support established projects that have moved beyond the realm of basic research and have the potential to result in a near-term impact in clinical research or the clinic. · Military Relevance: The proposed research must address at least one of the FY20 PRCRP Military Health Focus Areas. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. For more information, review the following websites: • PRCRP Vision Video (https://cdmrp.army.mil/pubs/video/prc/prcrp_vision_video) • PRCRP (https://cdmrp.army.mil/prcrp/default) • PRCRP Report to Congress (https://cdmrp.army.mil/prcrp/reports/reports) • Military Health System (MHS) (https://www.health.mil) • VA (https://www.va.gov/) A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within this funding opportunity and fit within the FY20 PRCRP priorities.
Catch-all / unrestricted eligibility mark · W81XWH-20-PRCRP-IPA
Grants.gov marks DoD Peer Reviewed Cancer Research with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).
- Code 99
- Unrestricted / see official listing
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
What to do next
DoD Peer Reviewed Cancer Research is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- Compare award ranges across federal categories before you pick a single CFDA. All categories
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |